ClinicalTrials.gg
RecruitingNCT04616495TRASMETIRUpdated Sep 22, 2023

Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases

An observational study in Colorectal Cancer, Metastatic Liver Cancer and Liver Metastases, sponsored by Hospital Universitario La Fe. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-09-22.

Sponsored by Hospital Universitario La Fe · Observational

How we know

From the registry’s dates

  • Started Sep 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 463 studies in Colorectal Neoplasms with a site in Spain — 97 open to participants now, 150 under way, 18 of them phase 3. Colorectal Neoplasms · Spain.

Planned enrollment
53rd of 55
30 · median 400
Started
2021
with 39 others
Observational
55 of 463
19 open now
Primary completion
2026-09
later than 39 of 149 live
Registered
275th of 463
by date

Among the 463 studies in Colorectal Neoplasms with a site in Spain, this one is the 53rd largest by planned enrollment of the 55 observational ones that give a count, is one of 40 that started in 2021, is one of 55 observational ones, reaches primary completion later than 39 of the 149 other live ones, and was the 275th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

97 of the 463 studies in Colorectal Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

92 more — sign in →

All 97 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 463 studies in Colorectal Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

Multicentric prospective and observational study to assess the 5-year overall survival in a cohort of patients with unresectable liver-only colorectal metastases, well controlled by chemotherapy prior to liver transplantation.

03

Conditions studied

  • Colorectal Cancer
  • Metastatic Liver Cancer
  • Liver Metastases
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Cohort of patients detected in oncological units where they have been treated for colorectal cancer (stage IV with liver only unresectable metastases)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 and ≤ years
  • Good performance status, 0 or 1
  • Resected adenocarcinoma in colon or rectum (R0 resection)
  • Unresectable liver
  • No extrahepatic disease
  • Normal blood tests
  • Response to ≤ 2 ( criteria)
  • ≥ 1 year period since diagnosis of colorectal cancer to enrolment in liver transplant waiting list
  • Signed

Exclusion criteria

Exclusion Criteria:

  • ≥ 30
  • Positive or
  • Pregnancy at the time of inclusion
  • BRAF mutated status
  • Deterioration of general condition (10% weight loss in the prior 6 months)
  • Other with disease free survival \< 5 years
  • Concomitant or prior extrahepatic (histologically or radiologically proved), even if surgically resected.
  • Palliative resection of primary colorectal adenocarcinoma
  • Liver metastases size > 5 cm (in the last imaging technique)
  • CEA > 80 ng/ml (at time of enrolment in waiting list)
  • No chemotherapy treatment
  • General to liver transplantation
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Liver transplanted patients

    Procedure: Liver transplantation

Interventions

  • ProcedureLiver transplantation

    Chemotherapy and liver transplantation

06

What researchers measure

Primary outcomes

  1. five year overall survival (OS)

    Time frame: 5 years

Secondary outcomes

  1. one year disease free survival (DFS)

    Time frame: 1 year

  2. three year disease free survival (DFS)

    Time frame: 3 years

  3. five year disease free survival (DFS)

    Time frame: 5 years

  4. Quality of life using EORTC questionnaires: QLQ-C30

    Time frame: 1 year

  5. Quality of life using EORTC questionnaires: QLQ-C30

    Time frame: 3 years

  6. Quality of life using EORTC questionnaires: QLQ-C30

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
  • Eva M Montalvá
    Valencia, 46026, Spain
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Sep 2026, 60 months after the start.

Of 531 non-industry observational studies under Colorectal Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 132. This study's planned 60 months is close to that.

Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2020
First posted
Nov 5, 2020
StartActual
Sep 1, 2021
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2028
Last update
Sep 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04616495
Lead sponsor
Hospital Universitario La Fe
Responsible party
Eva M. Montalvá (Hepatobiliarypancreatic and Transplant Surgeon, Hospital Universitario La Fe) — Principal investigator
First posted
Nov 5, 2020
Start date
Sep 1, 2021
Primary completion
Sep 2026 (estimated)
Completion
Sep 2028 (estimated)
Last update
Sep 22, 2023

Study contacts

Eva M Montalvá, PhD
Contact
montalva.oron@gmail.com
+34961245858

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion